High-Grade B-Cell Primary Pulmonary Lymphoma in Patients with an Underlying Disorder such as Immunodeficiency

This protocol addresses high-grade B-cell primary pulmonary lymphoma — a rare and aggressive subtype that arises predominantly in individuals with a predisposing underlying disorder, such as immunodeficiency. This histological subtype accounts for 11–19% of primary pulmonary lymphoma cases in published series.

Management in this setting typically begins with surgical resection. Following resection, a combination chemotherapy approach is generally applied — the specific regimens and eligibility criteria are detailed in the full structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

High-grade pulmonary B-cell lymphoma is far rarer and usually occurs in individuals with an underlying disorder (e.g. immunodeficiency).
High-grade NHL-B represents 11–19% of cases of PPL in published series; MALT-type NHL coexists in y50% of cases.
Treatment after surgical resection is often based on the combination chemotherapy regimens used for high-grade nodal NHL.

DOI: 10.1183/09031936.02.00404102

View source ↗